Eigen Bio / Foundry
Drug discovery & development
Foundry is Eigen Bio’s drug discovery and development business. We map resistance biology, identify target hypotheses and evaluate interventions designed to address treatment-persistent disease.
Mechanistic evidence. Candidate interventions. Experimental validation.
Explore connected biological routes that may sustain treatment-persistent disease.
Conceptual research illustration. Intervention hypotheses require experimental validation.
Drag or swipe horizontally to rotate. Arrow keys rotate the focused network, plus and minus zoom, Home resets, Space pauses motion and N explores the next anonymous target. Vertical touch gestures scroll the page. The three target hypotheses are illustrative and do not identify specific programs or measured effects.
Map resistance biology
Qualify intervention targets
Test the hypothesis
Foundry / Pipeline
Oncology programs built around assets with prior human PK data.
Evidence reviewed
Treatment-persistent prostate cancer.
Treatment-persistent colorectal cancer.
Bars show prior asset development reaching Phase 1. Eigen’s current work in the proposed indications is asset evaluation and validation preparation.
Our starting point
A useful therapeutic hypothesis begins with a precise question about a defined disease state.
We investigate the molecular and regulatory programs associated with persistence, response, and resistance. That context guides which mechanisms to examine, which targets to qualify, and which interventions may be relevant.
Eigen Bio’s Foundry approach connects this scientific work to the practical requirements of building a therapeutic program. Each stage makes the evidence, uncertainties, and next decision explicit.
The Foundry approach
A structured progression from disease biology to the experiments that determine what advances.
Specify the patient context, treatment history, unmet need, and biological state the program aims to address.
Bring transcriptomic signals, regulatory relationships, and independent evidence together around testable intervention hypotheses.
Examine the target’s role in the relevant state, the evidence for intervention, and the assumptions that need testing.
Assess candidate interventions with prior human exposure against the proposed mechanism and the requirements of a development program.
Choose experiments, readouts, and decision criteria that test the program’s central hypothesis.
Prior human exposure provides useful development evidence. Its relevance to a new indication, dose, schedule, or combination requires separate assessment.
Asset and program diligence
A mechanism needs an intervention with a credible path to evaluation.
Build with us
We welcome asset owners, translational researchers, and development partners.
Conversations may begin with an asset, a disease mechanism, or a validation capability. Together, we can define the evidence needed to evaluate licensing, research collaboration, or co-development.
Contact Eigen Bio
Explore how Eigen Bio’s scientific platform can inform a research or development decision.
